| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma | Phase 1 | 2023-11-01 |
| Terminated | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | 2021-05-27 |
| Terminated | A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma | Phase 1 | 2020-02-05 |
| Terminated | Study of MT-5111 in HER2-positive Solid Tumors HER2-positive Solid Cancers | Phase 1 | 2019-11-12 |
| Terminated | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalido Non-hodgkin Lymphoma | Phase 2 | 2019-04-08 |
| Terminated | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Tr Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | 2018-08-20 |
| Withdrawn | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for th Chronic B-cell Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 1 | 2015-11-01 |
| Terminated | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia | Phase 1 / Phase 2 | 2015-02-01 |
| No Longer Available | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma Non-Hodgkin's B-cell Lymphoma | — | — |